The inventor of Narcan, the nasal spray that can reverse an opioid overdose, said the decision by an Oklahoma judge to hold Johnson & Johnson responsible for fueling the state's opioid crisis is a major step in the nation's effort to combat the epidemic.
While the $570 million judgment was a fraction of the $17 billion requested by the state, Dr. Roger Crystal said that it illustrates "that the states are taking this crisis very seriously."
Narcan, which administers naloxone, blocks opioid receptor sites in a person's nervous system and can reverse the effects of an overdose — if administered quickly enough.
The nasal spray was first approved by the federal Food and Drug Administration in November 2015. Since then, the product has been used countless times to reverse overdoses from opioids, which include drugs such as oxycodone, hydrocodone, morphine, and illegal fentanyl, among others.
<i>The opioid epidemic in 2017 by the numbers. Credit: U.S. Department of Health and Human Services</i>
Each dose costs roughly $37, which, Crystal said is "totally appropriate" for a drug that can save a life. Still, roughly 130 people die everyday from opioid overdoses, according to government estimates.
The Johnson & Johnson decision is a "recognition of a serious opioid crisis," Crystal said, adding that opioids have "been the biggest killer of young Americans."
Crystal added, however, that while opioid manufacturers have "significantly contributed" to the crisis, addressing the issue will require a broader restructuring of how painkillers are prescribed and how doctors approach pain management.
Monday's court ruling also coincides with International Overdose Awareness Day, which is observed every year on August 31.
Lower Manhattan's iconic Stone Street is getting a bubbly makeover. Champagne Nicolas Feuillatte will be 'unleashing the bubbles' throughout the month of June in New York City, with themed events, bubble ball pits, and special menu and drink experiences. Anne-Laure Domenichini, director of communications for Champagne Nicholas Feuillatte, joins Cheddar News' Closing Bell to discuss.
The courtroom drama "All Rise" is returning for a brand new season and has a new home on OWN: The Oprah Winfrey Network. The stars of the series, Wilson Bethel and executive producer Simone Missick, discuss what to expect.
API platform RapidAPI recently became a unicorn with a $1 billion valuation after raising $150 million in a Series D funding round led by Softbank Vision Two Fund. Microsoft's Venture Fund, M12, and Andreessen Horowitz also participated. RapidAPI says it provides the world's largest API hub which enables millions of developers and companies to build software faster. Iddo Gino, founder and CEO of RapidAPI, joins Cheddar News' Closing Bell to discuss.
Sports merchandising company Fanatics announced it will be making trading cards featuring college athletes, a deal made possible by the NCAA's change to NIL rules for its players. Anchors Kristen Scholer and Ken Buffa break down the deal for Cheddar.
In a recent Bumble survey, more than a third of respondents revealed that they would be willing to date people in other cities. Shan Boodram, a sex and relationships expert for the app, joined Cheddar News to talk about the long-distance dating trend and tips on how to go about taking part. "I think this is the magic of what we experienced over the past couple of years, is that we have already learned the tools necessary to stay connected with people despite not being able to be close to them," she noted. Boodram also pointed to Bumble's travel mode and using video conferencing in order to ease into such relationships.
Amanda Victoria, co-founder and CEO of Siponey, joins Cheddar News to talk about the company's canned cocktails. The spritz is made with only four ingredients — wildflower honey, aged rye whiskey, sparkling water, and fresh lemon juice.
Rick Pauls, President & CEO OF DiaMedica Therapeutics, joins Cheddar Innovates to discuss a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients.
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
